ProCE Banner Activity

Expanding Therapeutic Horizons: Targeting Non-V600 BRAF Mutations in Solid Tumors

Clinical Thought

In this commentary, an expert addresses the importance of targeting non-V600 BRAF alterations in cancer and the emerging data on investigational agents targeting these alterations in patients.

Released: August 02, 2023

Share

Faculty

Alexander Spira

Alexander Spira, MD, PhD, FACP

Director                                                                                                                                                                        NEXT Oncology Virginia
Clinical Assistant Professor
Johns Hopkins
Co-Director                                                                                                                                                                    Clinical Research
Virginia Cancer Specialists
Fairfax, Virginia

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Kinnate Biopharma.

Kinnate Biopharma

Faculty Disclosure

Primary Author

Alexander Spira, MD, PhD, FACP

Director                                                                                                                                                                        NEXT Oncology Virginia
Clinical Assistant Professor
Johns Hopkins
Co-Director                                                                                                                                                                    Clinical Research
Virginia Cancer Specialists
Fairfax, Virginia

Alexander Spira, MD, PhD, FACP: consultant: Amgen, Array, AstraZeneca/Medimmune, Bristol Myers Squibb, Gritstone Oncology, Incyte, Janssen, Jazz, Merck, Mirati, Novartis; researcher: AbbVie, ADCT, Amgen, Arch, Astellas, Astex, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Gritstone, Incyte, Ignyta, Janssen, LAM Therapeutics, Loxo, Macrogenics, MedImmune, Mirati, Newlink Genetics, Novartis, Plexxikon, Roche, Rubius, Takeda, Trovagene; ownership interest: Lilly.